NCT07034222View on ClinicalTrials.gov

12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Alzheimer's Disease(AD)
Interventions
DRUG

Administer Leqemi 10 mg/kg, every two weeks.

Receive 10 mg/kg of Leqembi once every two weeks. Dissolve Leqembi in normal saline and administer it intravenously over 60 minutes. The infusion system must use a 0.2-μM terminal line filter for administration.

Trial Locations (1)

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT07034222 - 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease | Biotech Hunter | Biotech Hunter